<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>off-the-shelf cellular therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/off-the-shelf-cellular-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 26 Nov 2025 22:50:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>off-the-shelf cellular therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Allogeneic iPSC-iNKT Cells Tested in Recurrent Head, Neck Cancer</title>
		<link>https://bioengineer.org/allogeneic-ipsc-inkt-cells-tested-in-recurrent-head-neck-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 26 Nov 2025 22:50:01 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Allogeneic iPSC-iNKT therapy]]></category>
		<category><![CDATA[Head and neck cancer immunotherapy]]></category>
		<category><![CDATA[iNKT cells clinical trial]]></category>
		<category><![CDATA[off-the-shelf cellular therapy]]></category>
		<category><![CDATA[Phase 1 cancer trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/allogeneic-ipsc-inkt-cells-tested-in-recurrent-head-neck-cancer/</guid>

					<description><![CDATA[In a groundbreaking advancement that holds promise for the treatment of recurrent head and neck cancer, researchers have unveiled the results of a pioneering phase 1 clinical trial employing allogeneic induced pluripotent stem cell (iPSC)-derived invariant natural killer T (iNKT) cells. This innovative therapeutic strategy leverages cutting-edge stem cell technology combined with the unique immunological [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">301915</post-id>	</item>
		<item>
		<title>UCLA Researchers Create Universal Single-Product Immunotherapy for Breast Cancer</title>
		<link>https://bioengineer.org/ucla-researchers-create-universal-single-product-immunotherapy-for-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 22 Oct 2025 19:35:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR-NKT cell therapy]]></category>
		<category><![CDATA[mesothelin-targeted therapy]]></category>
		<category><![CDATA[off-the-shelf cellular therapy]]></category>
		<category><![CDATA[triple-negative breast cancer]]></category>
		<category><![CDATA[triple-negative breast cancer treatment]]></category>
		<category><![CDATA[UCLA cancer research]]></category>
		<category><![CDATA[universal immunotherapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ucla-researchers-create-universal-single-product-immunotherapy-for-breast-cancer/</guid>

					<description><![CDATA[Triple-negative breast cancer (TNBC) has long posed a formidable challenge within oncology, notorious for its aggressive nature and limited treatment avenues. Unlike other breast cancer subtypes, TNBC lacks expression of estrogen receptors, progesterone receptors, and HER2 proteins, which have traditionally served as therapeutic targets for more personalized and effective treatment regimens. This absence of molecular [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">285388</post-id>	</item>
	</channel>
</rss>
